Related Experiment Video
Updated: Feb 13, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Gao Zhang1, Lawrence W Wu1, Ilgen Mender2
1Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.
Abstract:
Purpose: Telomerase promoter mutations are highly prevalent in human tumors including melanoma. A subset of patients with metastatic melanoma often fail multiple therapies, and there is an unmet and urgent need to prolong disease control for those patients.Experimental Design: Numerous preclinical therapy-resistant models of human and mouse melanoma were used to test the efficacy of a telomerase-directed nucleoside, 6-thio-2'-deoxyguanosine (6-thio-dG). Integrated transcriptomics and proteomics approaches were used to identify genes and proteins that were significantly downregulated by 6-thio-dG.Results: We demonstrated the superior efficacy of 6-thio-dG both in vitro and in vivo that results in telomere dysfunction, leading to apoptosis and cell death in various preclinical models of therapy-resistant melanoma cells. 6-thio-dG concomitantly induces telomere dysfunction and inhibits the expression level of AXL.Conclusions: In summary, this study shows that indirectly targeting aberrant telomerase in melanoma cells with 6-thio-dG is a viable therapeutic approach in prolonging disease control and overcoming therapy resistance. Clin Cancer Res; 24(19); 4771-84. ©2018 AACR See related commentary by Teh and Aplin, p. 4629.
Insights
A novel telomerase-directed nucleoside, 6-thio-2'-deoxyguanosine (6-thio-dG), effectively treats therapy-resistant melanoma by inducing telomere dysfunction and apoptosis. This approach offers a promising strategy to prolong disease control in metastatic melanoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Telomerase promoter mutations are common in human tumors, including melanoma.
- Metastatic melanoma patients often exhibit resistance to multiple therapies, necessitating new treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of 6-thio-2 -deoxyguanosine (6-thio-dG), a telomerase-directed nucleoside, against therapy-resistant melanoma.
- To identify molecular targets and pathways affected by 6-thio-dG treatment in melanoma.
Main Methods:
- Utilized preclinical models of therapy-resistant human and mouse melanoma.
- Applied integrated transcriptomics and proteomics to identify downregulated genes and proteins.
- Assessed the in vitro and in vivo efficacy of 6-thio-dG.
Main Results:
- 6-thio-dG demonstrated superior efficacy in preclinical melanoma models.
- Treatment induced telomere dysfunction, apoptosis, and cell death.
- 6-thio-dG inhibited the expression of AXL and downregulated specific genes/proteins.
Conclusions:
- 6-thio-dG is a viable therapeutic approach for targeting aberrant telomerase in melanoma.
- This strategy can prolong disease control and overcome therapy resistance in melanoma.
- Targeting telomerase with 6-thio-dG offers a new avenue for treating resistant melanoma.
More Related Videos
Related Concept Videos
Telomeres and Telomerase
Telomeres and Telomerase
Gene Therapy
Resistivity
Resistance
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

